Federated Hermes, Inc. Bei Gene, Ltd. Transaction History

Federated Hermes, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 13, 2018	SELL	$152.62 - $189.66 $518,908 - $644,844	-3,400 Reduced 42.5%	4,600 $792,000
Q2 2018 Aug 10, 2018	SELL	$152.5 - $216.77 $152,500 - $216,770	-1,000 Reduced 11.11%	8,000 $1.23 Million
Q1 2018 May 09, 2018	BUY	$97.41 - $177.22 $876,690 - $1.59 Million	9,000 New	9,000 $1.51 Million

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.